Immunic Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, has welcomed seasoned biopharmaceutical executive, Jason Tardio, as Chief Operating Officer and President, effective July 12, 2024. In the newly created role, Tardio will lead internal efforts to prepare for the potential launch of vidofludimus calcium (IMU-838), the company’s orally available nuclear receptor related 1 ...